S-64315

N/A

Report date: 2022/12/20 20:00:19
NME

Base Information

Drug NameS-64315
Drug Alias NameMIK-665S-64315
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInduced myeloid leukemia cell differentiation protein Mcl-1 inhibitors
TargetsInduced myeloid leukemia cell differentiation protein Mcl-1
Therapy Area/IndicationsMyelodysplastic SyndromesMultiple MyelomaLymphoma, Large B-Cell, Diffuse +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyAustralia +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesLes Laboratoires ServierVernalis Plc
China Registration ClassN/A

Develop Information

Active CompaniesAdir SarlInstitut De Recherches Internationales Servier
Inactive CompaniesNovartis Pharma Ag
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsMyelodysplastic SyndromesMultiple MyelomaLymphoma, Large B-Cell, Diffuse

Other Information

ATC CodeN/A
Related LinksN/A